我們已在上線!
進一步了解
GLS
Gelesis Holdings, Inc.
GLS
GLS
已下市
GLS已於2023年4月10日下市。
關於: Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.
員工: 93
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
0%
負面
0%
我們尚未收到任何關於GLS的最新新聞文章。
價格圖表採用Lightweight Charts™實作